June 12, 2026 Announcements NOTICE OF PRESCRIPTION DRUG PRICE TRANSPARENCY ANNUAL MEETING The Office of the Superintendent of Insurance will hold its annual public meeting to present and discuss the findings and recommendations contained in the 2025 Prescription Drug Price Transparency legislative report. The purpose of this meeting is to inform the public of the report’s contents and to provide an opportunity for public comments and questions. Members of the public are invited and encouraged to attend this virtual meeting. Participants will have the opportunity to submit questions and provide oral comments during the presentation. This meeting will be conducted virtually via Webex. To participate, click the link below or copy and paste it into your browser. No prior registration is required. Meeting Details: Date: June 26, 2026Time: 2:00 pmFormat: Online via WebexWebex Link: https://teams.microsoft.com/meet/284287490769003?p=RlMEO52OXI7yxaqxh2Meeting ID: 284 287 490 769 003Passcode: SM7Cz2AX Thank you for your interest and participation. If you have any questions about this notice or the meeting itself, please feel free to reach out to: Alejandro AmparanDirector of Pharmacy Benefits and Drug CompliancePhone: 505-607-5996Email: RxTransparency@osi.nm.gov NOTICE OF PRESCRIPTION DRUG PRICE TRANSPARENCY ANNUAL MEETING
June 26, 2026 Bulletins MEDICAL MALPRACTICE PREMIUM REDUCTION AMENDED BULLETIN 2026-010: The New Mexico State Legislature appropriated $5 million to the New Mexico Office of Superintendent of Insurance (OSI) to address medical malpractice insurance costs for individual providers. The appropriation was part of a supplemental appropriation package passed in 2025. This one-time appropriation directs OSI to provide a premium subsidy for private medical malpractice insurance policies. […] Read More
June 12, 2026 Announcements NOTICE OF PRESCRIPTION DRUG PRICE TRANSPARENCY ANNUAL MEETING The Office of the Superintendent of Insurance will hold its annual public meeting to present and discuss the findings and recommendations contained in the 2025 Prescription Drug Price Transparency legislative report. The purpose of this meeting is to inform the public of the report’s contents and to provide an opportunity for public comments and questions. […] Read More
